What is Carfilzomib?

Category: Prescription Drugs

Most popular types: Kyprolis

false

See also: Carfilzomib-cyclophosphamide-dexamethasone Carfilzomib-dexamethasone Carfilzomib-lenalidomide-dexamethasone

Carfilzomib is an injectable antineoplastic product used for the treatment of multiple myeloma. This agent helps the body stop or slow the production of unwanted cancer cells and as a result may work to inhibit tumor growth.

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 4
Moderate 9
Mild 3
None 0

Commonly reported side effects and conditions associated with Carfilzomib

Side effect Patients Percentage
Fatigue 4
Nausea 2
Peripheral neuropathy 2
Anemia of chronic disease 1
Blood clot 1
Diarrhea 1

Show all 18 reported side effects

Dosages

Based on patients currently taking Carfilzomib

Dosage Patients Percentage
60 mg weekly 1

Why patients stopped taking Carfilzomib

Multiple reasons could be selected

Reason Patients Percentage
Side effects too severe 4
Other 2
Course of treatment ended 1
Did not seem to work 1
Doctor's advice 1
See all 9 patients who've stopped taking Carfilzomib

Duration

Currently taking Carfilzomib

Duration Patients Percentage
2 - 5 years 1

Stopped taking Carfilzomib

Duration Patients Percentage
Less than 1 month 2
1 - 6 months 3
6 months - 1 year 2
1 - 2 years 1
2 - 5 years 1
Adherence
Adherence Evaluations Percentage
Always 12
Usually 2
Sometimes 0
Never taken as prescribed 2
Burden
Burden Evaluations Percentage
Very hard to take 3
Somewhat hard to take 3
A little hard to take 5
Not at all hard to take 5
Cost per month
Cost per month Evaluations Percentage
$200+ 1
$100-199 1
$50-99 0
$25-49 0
< $25 7
Not specified 7

What people switch to and from

Patients started taking Carfilzomib after stopping:

Treatment Patients Percentage
Bortezomib (Velcade) 3
Lenalidomide (Revlimid) 3
Bortezomib-lenalidomide-dexamethasone (VRd) 1
Elotuzumab (Empliciti) 1
Ixazomib (Ninlaro) 1

Show all 7 treatments patients report switching from

Patients stopped taking Carfilzomib and switched to:

Treatment Patients Percentage
Daratumumab (Darzalex) 2
Daratumumab-lenalidomide-dexamethasone (DRd) 1
Ixazomib (Ninlaro) 1
Lenalidomide (Revlimid) 1
Pomalidomide (Pomalyst) 1
Last updated:
There are no evaluations for Carfilzomib.